Inhibrx Biosciences, Inc. (INBX)
Develops experimental cancer-fighting drugs using engineered proteins.
$79.68-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+268.9%
The outlook
INBX is trading below both its 50- and 200-day moving averages, placing it in the lower half of its 52-week range. Analyst sentiment leans bearish overall, though the average price target sits roughly 2.5x above the current price, suggesting a wide gap between near-term momentum and longer-term analyst expectations.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range44% of the way from its 52-week low to high
Price targetAvg target +248% vs current price
Analyst price target
~12-month · 2 analysts$277.50average target+248.3% vs now
Now $79.68
Low $230.00High $325.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.17B
52-wk high
$155.29
52-wk low
$20.55
50-day avg
$95.59
200-day avg
$82.84
Trailing P/E
—